Table 3 Tumour margin status by molecular subtype in studied patients (n = 295).
Molecular subtype | Tumour margin | Total | p-value | ||
|---|---|---|---|---|---|
Involved | Free | Close | |||
No. (%) | |||||
Luminal A | 10 (12.33) | 61 (75.29) | 5.0 (6.2) | 76 (27) | 0.043* |
Luminal B | 12 (10.3) | 102 (87.2) | 3.0 (2.6) | 117 (39) | |
Luminal B-HER2+ | 4.0 (5.8) | 60 (87.0) | 5.0 (7.2) | 69 (23) | |
Low HER2 overexpression | 0.0 (0.0) | 0.0 (0.0) | 1.0 (100) | 1.0 (0.33) | |
High HER2 overexpression | 0.0 (0.0) | 7.0 (77.8) | 2.0 (22.2) | 9.0 (3.0) | |
Triple-negative breast cancer | 1.0 (4.3) | 21 (91.3) | 1.0 (4.3) | 23 (7.7) | |
Total | 27 (9.03) | 251 (83.79) | 17 (5.7) | 295 (100) | |
